Ligand Targretin gel
Executive Summary
Topical bexarotene 1% formulation approved June 28 for treatment of cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma who have refractory or persistent disease after other therapies or have not tolerated other therapies. Targretin capsules were approved Dec. 29 as a second-line CTCL treatment (1"The Pink Sheet" Jan. 10, p. 3)
You may also be interested in...
Targretin Is Second Product In Ligand CTCL Therapy Triple Offering
The approval of Targretin capsules is the second step in Ligand's plan to offer patients with cutaneous T-cell lymphoma treatment options for all stages of the disease. The company currently markets Ontak and recently submitted an NDA for Targretin Gel.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials